ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 1712 • ACR Convergence 2024

    Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment

    Yulong Tang1, Jiangnan Xie2, Dachun Zhuo1, Qi ZHU3, Jiucun Wang1 and Jing Liu2, 1Fudan University, Shanghai, China (People's Republic), 2Fudan University, Shanghai, Shanghai, China (People's Republic), 3Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China (People's Republic)

    Background/Purpose: Ankylosing spondylitis (AS) is an autoimmune and auto-inflammatory disease characterized by chronic inflammation of the spine, sacroiliac joint, and occasionally peripheral joints. TNF-α inhibitor…
  • Abstract Number: 2363 • ACR Convergence 2024

    “How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies

    Atul Deodhar1, Elena Nikiphorou2, Abhijeet Danve3, Stephen Hall4, Vanessa Taieb5, Diana Voiniciuc6, Marina Magrey7 and Xenofon Baraliakos8, 1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 2King's College London, London, United Kingdom, 3Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, 4Cabrini Medical Centre, Monash University, and Emeritus Research, Melbourne, Victoria, Australia, 5UCB Pharma, Colombes, France, 6UCB Pharma, Slough, United Kingdom, 7Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, 8Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Two phase 3 studies were conducted where treatment…
  • Abstract Number: L11 • ACR Convergence 2023

    Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study

    Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, Yong-Beom Park and Min-Chan Park, Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose: Patients with ankylosing spondylitis (AS) have a higher risk of cardiovascular events than controls. Although biological disease-modifying anti-rheumatic drugs (bDMARDs) are efficacious in treating…
  • Abstract Number: 0510 • ACR Convergence 2023

    Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies

    Philip J. Mease1, Maxime Dougados2, Maureen Dubreuil3, Marina Nighat Magrey4, Helena Marzo-Ortega5, Martin Rudwaleit6, Christine de la Loge7, Carmen Fleurinck8, Ute Massow9, Vanessa Taieb10 and Atul Deodhar11, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 2Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France, 3Department of Rheumatology, Boston University School of Medicine, Milton, MA, 4Case Western Reserve University, University Hospitals, Cleveland, OH, 5NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 6University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Oosterzele, Belgium, 9UCB Pharma, Monheim am Rhein, Germany, 10UCB Pharma, Colombes, France, 11Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…
  • Abstract Number: 0541 • ACR Convergence 2023

    Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study

    Irini Flouri1, Nestor Avgoustidis2, Anastasios Eskitzis2, Argyro Repa2, Katerina Pateromichelaki2, Sofia Pitsigavdaki3, Myrto Nikoloudaki2, Maria Terizaki2, George Bertsias4 and Prodromos Sidiropoulos4, 1University of Crete Medical School, Heraklion, Greece, 2Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, 3Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, 4Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece

    Background/Purpose: Data regarding the adoption of the treat-to-target (T2T) approach aiming at inactive disease (ID), or low disease activity (LDA) in axial (axSpA) and peripheral…
  • Abstract Number: 1397 • ACR Convergence 2023

    Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials

    Victoria Navarro-Compán1, Lianne Gensler2, Martin Rudwaleit3, Fabiana Ganz4, Shirley Chen4, Jayne Stigler4, Anna Schmagel4 and Xenofon Baraliakos5, 1Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 2University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 3University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 4AbbVie, Inc., North Chicago, IL, 5Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany

    Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…
  • Abstract Number: 1788 • ACR Convergence 2023

    The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis

    Sungsin Jo1, Seung Hoon Lee1, Chanhyeok Jeon1, Sung Hoon Choi2, Ye-Soo Park3 and Tae-Hwan Kim4, 1Hanyang University Institute for Rheumatology Research, Seoul, South Korea, 2Hanyang University Seoul Hospital, Seoul, South Korea, 3Hanyang University College of Medicine, Guri, South Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Enthesitis is one of the most distinctive features and signs of ectopic bone formation in ankylosing spondylitis (AS). The Wnt/β-catenin pathway and Th17 cells…
  • Abstract Number: 2549 • ACR Convergence 2023

    Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT

    Walter P. Maksymowych1, Robert Lambert2, Eswar Krishnan3, Baojin Zhu3, Rebecca Bolce3 and Mikkel Østergaard4, 1University of Alberta, Edmonton, AB, Canada, 2Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 3Eli Lilly and Company, Indianapolis, IN, 4Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: The effect of Ixekizumab (IXE) on structural lesions in the sacroiliac joints (SIJ) of patients (pts) with radiographic Axial Spondylarthritis (r-axSpA) assessed by magnetic…
  • Abstract Number: 0515 • ACR Convergence 2023

    Dose Adjustment of Tumor Necrosis Factor Inhibitors Does Not Correlated with Radiographic Progression in Patients with Ankylosing Spondylitis

    Bon San Koo1, Seo Young Park2, Ji Hui Shin3, Seunghun lee3, kyung bin Joo3 and Tae-Hwan Kim4, 1Inje University Seoul Paik Hospital, Seoul, South Korea, 2Korea National Open University, Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Among patients with ankylosing spondylitis (AS) treated with tumor necrosis factor (TNF) inhibitors, tapering the dose of TNF inhibitors may be considered for patients…
  • Abstract Number: 0775 • ACR Convergence 2023

    Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study

    Amy Peeters, C.A.J Michielsens, Elien Mahler, Lise Verhoef, Alfons den Broeder, Nathan den Broeder and Noortje van Herwaarden, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are effective in PsA and axial SpA, but are associated with increased infections risk, patient burden and high costs.…
  • Abstract Number: 1399 • ACR Convergence 2023

    Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data

    Ansaam Daoud1, Sadeer Al-Kindi2 and Marina Nighat Magrey3, 1University Hospitals, Case Western Reserve University, Akron, OH, 2Case Western Reserve University/University Hospitals, Cleveland, OH, 3Case Western Reserve University, University Hospitals, Cleveland, OH

    Background/Purpose: Ankylosing Spondylitis (AS) is associated with an increased risk of cardiovascular disease, partly due to systemic inflammation, and an increased risk of vascular mortality.…
  • Abstract Number: 1789 • ACR Convergence 2023

    Microtrauma Exacerbates Arthritis and Enthesitis in Curdlan-administered SKG Mice by Inducing FGF16 Expresssion

    Seung Hoon Lee1, Chanhyeok Jeon1, Sungsin Jo1 and Tae-Hwan Kim2, 1Hanyang University Institute for Rheumatology Research, Seoul, South Korea, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Microtrauma might be considered a crucial of various environmental factors in AS, but there is still unknown whether microtrauma has a direct/indirect role in…
  • Abstract Number: 2563 • ACR Convergence 2023

    Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study

    Ying Hu1, Hongyi He2, Yuqing Zhang3, Houchen Lyu4, Chao Zeng2, Jie Wei5 and Guanghua Lei2, 1Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China, 2Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, 3Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 4Chinese PLA General Hospital, Department of Orthopedics, Beijing, China, 5Health Management Center, Xiangya Hospital Central South University, Changsha, China

    Background/Purpose: Gut microbiota has been increasingly recognized as important and novel targets for rheumatic diseases. However, previous studies mostly examined the associations, leaving causality largely…
  • Abstract Number: 0518 • ACR Convergence 2023

    Tofacitinib Efficacy and Safety in Patients with Ankylosing Spondylitis by Baseline C-Reactive Protein Levels: A Post Hoc Analysis

    Atul Deodhar1, Xenofon Baraliakos2, Marina Nighat Magrey3, Lianne Gensler4, Amit V. Thorat5, Surya Pemmaraju6, Mary Jane Cadatal7 and Peter Nash8, 1Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3Case Western Reserve University, University Hospitals, Cleveland, OH, 4University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 5Pfizer Australia, Sydney, Australia, 6Pfizer Inc., Chennai, Tamil Nadu, India, 7Pfizer Inc., Manila, Philippines, 8School of Medicine, Griffith University, Brisbane, Australia

    Background/Purpose: Elevated baseline (BL) CRP levels can predict treatment response in patients (pts) with AS. Tofacitinib is a Janus kinase inhibitor for the treatment of…
  • Abstract Number: 0844 • ACR Convergence 2023

    Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort

    Manouk de Hooge1, Rosalinde Stal2, Alexandre Sepriano3, Xenofon Baraliakos4, Monique Reijnierse5, Juergen Braun6, Désirée van der Heijde7, Floris Van Gaalen2 and Sofia Ramiro7, 1Ghent University Hospital, Hesperange, Luxembourg, 2Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, 3Leiden University Medical Centre, Portela Loures, Portugal, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5Leiden University Medical Center, Leiden, Netherlands, 6Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, 7Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: To assess whether posterior element (PE) inflammation, in particular in the facet joints (FJ), is associated with new facet joint ankylosis on MRI one…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology